Endometrial cancer - reduce to the minimum. A new paradigm for adjuvant treatments?

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Scheithauer, Heike R ^a   Schulz, Diana S ^a   Belka, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL HYSTERECTOMY; BRACHYTHERAPY; CANCER RADIOTHERAPY; ENDOMETRIUM CANCER; HUMAN; LYMPH NODE DISSECTION; MEDLINE; OVERALL SURVIVAL; RECURRENT CANCER; REVIEW; SALPINGOOOPHORECTOMY; ADJUVANT THERAPY; ENDOMETRIUM TUMOR; FEMALE; LYMPHADENECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BRACHYTHERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82055181814     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-164     Document Type: Review

References (33)

1. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer 1987, 60(8 Suppl):2035-41.
2. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol 1991, 40(1):55-65. 10.1016/0090-8258(91)90086-K, 1989916.
3. Alektiar KM, McKee A, Venkatraman E, McKee B, Zelefsky MJ, Mychalczak BR, et al. Intravaginal high-dose-rate brachytherapy for stage IB (FIGO grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys 2002, 53(3):707-13. 10.1016/S0360-3016(02)02792-X, 12062616.
4. Dickler A, Puthawala MY, Thropay JP, Bhatnagar A, Schreiber G. Prospective multi-center trial utilizing electronic brachytherapy for the treatment of endometrial cancer. Radiat Oncol 2010, 5:67. 10.1186/1748-717X-5-67, 2914666, 20646289.
5. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the society of gynecologic oncologists in 2005. Gynecol Oncol 2007, 105(1):7-12. 10.1016/j.ygyno.2006.11.003, 17187847.
6. Naumann RW, Higgins RV, Hall JB. The use of adjuvant radiation therapy by members of the society of gynecologic oncologists. Gynecol Oncol 1999, 75(1):4-9. 10.1006/gyno.1999.5548, 10502417.
7. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A gynecologic oncology group study. Gynecol Oncol 2004, 92(3):744-51. 10.1016/j.ygyno.2003.11.048, 14984936.
8. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000, 355(9213):1404-11. 10.1016/S0140-6736(00)02139-5, 10791524.
9. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005, 23(16):3668-75. 10.1200/JCO.2005.04.144, 15738538.
10. Seago DP, Raman A, Lele S. Potential benefit of lymphadenectomy for the treatment of node-negative locally advanced uterine cancers. Gynecol Oncol 2001, 83(2):282-5. 10.1006/gyno.2001.6379, 11606085.
11. Fanning J. Long-Term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001, 82(2):371-4. 10.1006/gyno.2001.6276, 11531297.
12. Smith DC, Macdonald OK, Lee CM, Gaffney DK. Survival impact of lymph node dissection in endometrial adenocarcinoma: A surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer 2008, 18(2):255-61. 10.1111/j.1525-1438.2007.01020.x, 17624991.
13. Poulsen HK. The danish endometrial cancer study (DEMCA). Acta Oncol 1989, 28(4):589-93. 10.3109/02841868909092277, 2789838.
14. Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock JE, et al. [Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish endometrial cancer group]. Ugeskr Laeger 1997, 159(22):3403-7.
15. Creutzberg CL. GOG-99: Ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?. Gynecol Oncol 2004, 92(3):740-3. 10.1016/j.ygyno.2004.01.009, 14984935.
16. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The postoperative radiation therapy in endometrial carcinoma trial. J Clin Oncol 2004, 22(7):1234-41. 10.1200/JCO.2004.08.159, 15051771.
17. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-Year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011,
18. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial. Int J Radiat Oncol Biol Phys 2001, 51(5):1246-55. 10.1016/S0360-3016(01)01765-5, 11728684.
19. Ng TY, Nicklin JL, Perrin LC, Cheuk R, Crandon AJ. Postoperative vaginal vault brachytherapy for node-negative stage II (occult) endometrial carcinoma. Gynecol Oncol 2001, 81(2):193-5. 10.1006/gyno.2001.6130, 11330948.
20. Chadha M, Nanavati PJ, Liu P, Fanning J, Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 1999, 75(1):103-7. 10.1006/gyno.1999.5526, 10502434.
21. Rittenberg PV, Lotocki RJ, Heywood MS, Krepart GV. Stage II endometrial carcinoma: Limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecol Oncol 2005, 98(3):434-8. 10.1016/j.ygyno.2005.04.030, 16005498.
22. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis. Lancet 2009, 373(9658):137-46. 2646125, 19070891.
23. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009, 373(9658):125-36. 2646126, 19070889.
24. Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: Are conclusions valid?. Gynecol Oncol 2010, 116(3):293-4. 10.1016/j.ygyno.2009.10.065, 19897230.
25. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 2010, 375(9717):816-23. 10.1016/S0140-6736(09)62163-2, 20206777.
26. Nout RA, van de Poll-Franse LV, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Long-Term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011, 29(13):1692-700. 10.1200/JCO.2010.32.4590, 21444867.
27. Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial. J Clin Oncol 2009, 27(21):3547-56. 10.1200/JCO.2008.20.2424, 19546404.
28. Eifel PJ. Radiotherapy: Intermediate-Risk endometrial cancer--adjuvant treatment. Nat Rev Clin Oncol 2010, 7(10):553-4. 10.1038/nrclinonc.2010.138, 20877416.
29. Chino JP, Jones E, Berchuck A, Secord AA, Havrilesky LJ. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 2011,
30. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. No lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008, 100(23):1707-16. 10.1093/jnci/djn397, 19033573.
31. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980, 56(4):419-27.
32. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Suvival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010, 375:1165-72. 10.1016/S0140-6736(09)62002-X, 20188410.
33. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001, 50(5):1145-53. 10.1016/S0360-3016(01)01566-8, 11483323.